Angiotensin-Converting Enzyme Inhibitors/therapeutic use; Captopril/therapeutic use; Diabetes Mellitus, Type 2/prevention & control; Humans; Hypertension/prevention & control; Randomized Controlled Trials as Topic; Receptor, Angiotensin, Type 1/drug effects; Renin-Angiotensin System/drug effects
Abstract :
[en] Most individuals with arterial hypertension or congestive heart failure are insulin-resistant and at a higher risk of developing type 2 diabetes (T2DM). The inhibition of the renin-angiotensin system (RAS), using an angiotensin converting enzyme inhibitor (ACEI) or a selective angiotensin receptor AT1 blocker (ARB), may exert favourable metabolic effects capable of preventing T2DM in high risk individuals. We performed a meta-analysis of randomised clinical trials (RCTs) assessing the effects of RAS inhibition on the incidence of new cases of T2DM in patients with arterial hypertension or congestive heart failure. Ten RCTs with cardiovascular prognosis as primary endpoints analysed the incidence of T2DM as secondary endpoints or as post-hoc analysis after a mean follow-up of 1 to 6 years: five with an ACEI and five with an ARB, compared with a placebo (n=4) or a reference drug (beta-blocker or diuretic: n=5; amlodipine: n=2). Eight RCTs concerned hypertensive patients: STOP Hypertension-2 (lisinopril or enalapril vs beta-blocker or diuretic), CAPPP (captopril vs thiazide or beta-blocker), HOPE (ramipril vs placebo), ALLHAT (lisinopril vs chlorthalidone and lisinopril vs amlodipine), LIFE (losartan vs atenolol), SCOPE (candesartan vs placebo), ALPINE (candesartan vs placebo) and VALUE (valsartan vs amlodipine). Two RCTs concerned patients with congestive heart failure: SOLVD (enalapril vs placebo) and CHARM-overall programme (candesartan vs placebo). Overall, 2 675 new cases of T2DM (7.40%) were observed in the group of 36 167 patients receiving a treatment with ACEI or ARA as compared with 3 842 events (9.63%) in the group of 39 902 control patients. A mean weighed relative risk reduction of new T2DM of 22% (95% CI: 18, 26; p<0.00001) was observed after RAS inhibition. The beneficial effect was similar with ACEIs and with ARBs as well as in patients with hypertension and in those with heart failure, and was also present whatever the comparator (placebo or beta-blockers/diuretics or amlodipine). The number needed-to-treat to avoid one new case of T2DM averaged 45 patients over 4-5 years. In conclusion, RAS inhibition consistently and significantly reduces the incidence of T2DM in individuals with arterial hypertension or with congestive heart failure. Considering the pandemic of T2DM, such pharmacological approach deserves further attention among the strategies aiming at preventing T2DM.
Disciplines :
Cardiovascular & respiratory systems Endocrinology, metabolism & nutrition
Author, co-author :
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Language :
English
Title :
Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials.
Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease. Hypertension, 2001, 37, 1053-9.
Reaven GM. Role of insulin resistance in human disease. Diabetes, 1988, 37, 1595-607.
DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care, 1991, 14, 173-94.
Gress TW, Nieto FJ, Shahar E, et al., for the Atherosclerosis Risk in Communities Study. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000, 342, 905-12.
Gurwitz JH, Bohn RL, Glynn RJ, et al. Antihypertensive drug therapy and the initiation of treatment for diabetes mellitus. Ann Intern Med, 1993, 118, 273-8.
Padwal R, Laupacis A. Antihypertensive therapy and incidence of type 2 diabetes. A systematic review. Diabetes Care, 2004, 27, 247-55.
Carey RM, Siragy HM. Newly recognized components of the reninangiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev, 2003, 24, 261-71.
Kaplan NM. Management of hypertension in patients with type 2 diabetes mellitus: guidelines based on current evidence. Ann Intern Med, 2001, 135, 1079-83.
Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs, 2004, 64, 2537-65.
Scheen AJ. Prevention of type 2 diabetes by inhibition of the reninangiotensin system: meta-analysis of randomized clinical trials (Abstract). Diabetes. 2004, 53 (Suppl 2), A85, 363-PD.
Review manager [RevMan) [Computer program]. In: Version 4.2 for Windws ed. Oxford, England: The Cochrane Collaboration; 2003.
Hansson L, Lindholm LH, Ekblom T et al., for the STOP-Hypertension-2 study group. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet, 1999, 354, 1751-6.
Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project [CAPPP) randomised trial. Lancet, 1999, 353, 611-6.
World Health Organization. Diabetes mellitus: report of a WHO Study Group. Technical Report Series 727. Geneva: WHO, 1985.
Scheen AJ. CAPPP trial [Letter). Lancet, 1999, 353, 1793-4.
Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Eng J Med, 2000, 342, 145-53.
Yusuf S, Gerstein H, Hoogwerf B, et al. Ramipril and the development of diabetes. JAMA, 2001, 286, 1882-5.
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT). JAMA, 2002, 288, 2981-97.
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report on the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 1997, 20, 1183-97.
Dahlöf B, Devereux RB, Kjeldsen SE, et al. for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study [LIFE): a randomised trial against atenolol. Lancet, 2002, 359, 995-1003.
Lindholm LH, Ibsen H, Borch-Johnsen K, et al., for the LIFE study group. Risk of new onset-diabetes in the Losartan Intervention For End-point reduction in hypertension study. J Hypertens, 2002, 20, 1879-86.
Lithell H, Hansson L, Skoog I, et al. for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens, 2003, 21, 875-86.
Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens, 2003, 21, 1563-74.
Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipidne: the VALUE randomised trial. Lancet, 14, 2004.
World Health Organization. Department of Non-Communicable Disease Surveillance. WHO 1999 criteria for diagnosis of diabetes mellitus. Geneva: World Health Organization, 1999, 1-59.
Pfeffer MA, Swedberg K, Granger CB et al., for the CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet, 2003, 362, 759-66.
McMurray JJV, Östergren J, Swedberg K et al., for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet, 2003, 362, 767-71.
Granger CB, McMurray JJV, Yusuf S et al., for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting- enzyme inhibitors: the CHARM-Alternative trial. Lancet, 2003, 362, 772-6.
Yusuf S, Pfeffer MA, Swedberg K et al., for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet, 2003, 362, 777-81.
The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med, 1992, 327, 685-91.
Vermes E, Ducharme A, Bourassa MG, Lessard M, White M, Tardif J-C. Enalapril reduces the incidence of diabetes in patients with chronic heart failure. Insight from the Studies Of Left Ventricular Dysfunction [SOLVD). Circulation, 2003, 107, 1291-6.
WHO Study Group. Prevention of diabetes mellitus: report of WHO study group. WHO Tech Rep Ser, 1994, 844, 1-100.
American Diabetes Association and National Institute of Diabetes, Digestive and Kidney Diseases. The prevention or delay of type 2 diabetes. Diabetes Care, 2002, 25, 742-9.
Davies MJ, Tringham JR, Troughton J, Khunti KK. Prevention of Type 2 diabetes mellitus. A review of the evidence and its application in a UK setting. Diabetic Med, 2004, 21, 403-14.
Scheen AJ. Le concept d'insulinosensibilité. Diab Metab, 2001, 27, 193-200.
Scheen AJ, Lefèbvre PJ. Insulin resistance vs insulin deficiency: which one comes first? The old question revisited. In: Di Mario U, Leonetti F, Pugliese G, Sbraccia P, Signore A, editors. Diabetes in the New Millennium. New York: Wiley & Sons, 2000, 101-13.
Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia, 2003, 46, 3-19.
Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance in essential hypertension. N Engl J Med, 1987, 317, 350-7.
Landsberg L. Insulin resistance and hypertension. Clin Exp Hypertens, 1999, 21, 885-94.
Paolisso G, De Riu S, Marrazzo G, Verza M, Varricchio M, D'Onofrio F. Insulin resistance and hyperinsulinemia in patients with chronic congestive heart failure. Metabolism, 1991, 40, 972-7.
Coats AJ, Anker SD, Anker S. Insulin resistance in chronic heart failure. J Cardiovasc Pharmacol, 2000, 35 [Suppl 4), S9-14.
Amato L, Paolisso G, Cacciatore F, et al. Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group. Diabetes Metab, 1997, 23, 213-8.
Tenenbaum A, Motro M, Fisman EZ, et al. Functional class in patients with heart failure is associated with the development of diabetes. Am Med, 2003, 114, 271-5.
Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med, 2002, 346, 393-403.
Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the Diabetes Prevention Program. Diabetes Care, 2003, 26, 977-980.
Chiasson J-L, Josse RG, Gomis R, et al., for the STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet, 2002, 359, 2072-7.
Scheen AJ. Preventing, delaying or masking type 2 diabetes with metformin in the Diabetes Prevention Program? [Letter). Diabetes Care, 2003, 26, 2701.
Chow L, De Gasparo M, Levens N. Improved glucose metabolism following blockade of angiotensin converting enzyme but not angiotensin AT1 receptors. Eur J Pharmacol, 1995, 282, 77-86.
Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension, 2002, 40, 609-11.
Engeli S, Negrel R, Sharma AM. Physiology and physiopathology of the adipose tissue renin-angiotensin system. Hypertension, 2000, 35, 1270-7.
Gorzelniak K, Engeli S, Janke J, Luft FC, Sharma AM. Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension. J Hypertens, 2002, 20, 965-73.
Scheen AJ. Current management strategies for coexisting diabetes mellitus and obesity. Drugs, 2003, 63, 1165-84.
Katovich MJ, Pachori A. Effects of inhibition of the renin-angiotensin system on the cardiovascular actions of insulin. Diabetes Obes Metab, 2000, 2, 3-14.
Ura N, Higashiura K, Shimamoto K. The mechanisms of insulin sensitivity improving effects of angiotensin converting enzyme inhibitor. Immunopharmacology, 1999, 44, 153-9.
Henriksen EJ, Jacob S. Angiotensin converting enzyme inhibitors and modulation of skeletal muscle insulin resistance. Diab Obes Metab, 2003, 5, 214-22.
Henriksen EJ, Jacob S. Modulation of metabolic control by angiotensin converting enzyme [ACE) inhibition. J Cell Physiol, 2003, 196, 171-9.
Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-activity. Circulation, 2004, 109, 2054-7.
Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension, 2004, 43, 1-10.
Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diab Metab, 2004, 30, 498-505.
